Dialogue Health Technologies Inc.

Financial performance has remained strong, with revenue growing from $23.61M in Q3 2022 to $25.54M in Q2 2023. Gross profit continued to perform well, with margins at 60% in the latest quarter. Operating income reached -$5.34M in Q2 2023, holding a steady -21% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$4.01M. Net income dropped to -$5.76M, keeping EPS at -$0.09. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.